-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 10, 2024

Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

Episodes in this series

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 9 Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 10 Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"

EP. 11 The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"

EP. 12 Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 13 Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dry eye | Image credit Kryuchka Yaroslav - stock.adobe.com

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

ByBrooke McCormick

July 13th 2026

alopecia hair loss | Image credit: Nadya Kolobova - stock.adobe.com

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain

BySkylar Jeremias

July 13th 2026

Alexander Spira, MD, PhD, FACP, FASCO | Image Credit: Virginia Cancer Specialists

The State of the Sarcoma Treatment Landscape: Alexander Spira, MD, PhD, FACP, FASCO

ByElla Hohmann, MS,Alexander Spira, MD, PhD, FACP, FASCO

July 13th 2026

kidneys | Image credit: Aliaksandr Marko - stock.adobe.com

Biologics Appear Renal-Safe in Psoriasis, IL-17 Agents Show Kidney Promise

BySkylar Jeremias

July 13th 2026

Dr Ajay K. Nooka

Ajay K. Nooka, MD, MPH, on MajesTEC-3 Data, Dropping Dexamethasone in MM

ByMaggie L. Shaw,Ajay K. Nooka, MD, MPH

July 13th 2026

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma